Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

- PMLiVE

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

- PMLiVE

Sandoz joins Europe’s MabThera biosimilar push

Novartis’ unit is second company to claim approval in Europe for biosimilar version

- PMLiVE

Sandoz UK promotes Tim de Gavre to country head

He succeeds Stephan Eder who becomes country head for Sandoz Germany

New analysis shows emergency hospital admissions for people with Multiple Sclerosis continue to rise

Updated data published by Wilmington Healthcare and the MS Trust highlights need for more preventative care for MS patients

Wilmington Healthcare

Case study: Multiple Sclerosis new medical device research

Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a...

Research Partnership

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

- PMLiVE

Novartis talks the talk with new MS digital tools

Presents real world terms in online dictionary and Chrome Extension

- PMLiVE

NOR-SWITCH – the final piece in the biosimilar puzzle?

As more biosimilars become available globally, physicians, payers and patients alike are keen to understand the safety of switching

- PMLiVE

Teva hit with largest-ever fine under US anti-corruption act

Company to pay $519m after promoting Copaxone in Russia, Ukraine and Mexico

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links